Transchem Limited reported a net profit of ₹429.51 lakh for the financial year ended March 31, 2026, down from ₹522.59 lakh in the prior year. The decline was driven by the absence of revenue from operations, as the company wound down its agricultural trading activities, and an increase in employee benefit expenses to ₹124.44 lakh from ₹67.00 lakh. Total income stood at ₹926.08 lakh, primarily derived from other income sources including interest on inter-corporate deposits and a capital gain from property sale. The Board has resolved not to recommend a dividend for FY26 to conserve resources for its strategic transition into the financial services sector.

The company’s 49th Annual General Meeting is scheduled for September 05, 2026, via video conferencing. Shareholders will consider the adoption of audited financial statements for FY26 and the re-appointment of Whole Time Director Mahesh Suresh Rananavre. Additionally, members are sought to approve material related party transactions with Crest Ventures Limited (CVL) for infrastructure and support services, capped at ₹5,00,000 over two financial years. The remote e-voting period runs from September 01, 2026, to September 04, 2026, with the book closure from August 30, 2026, to September 05, 2026.

Financial Performance Highlights

The following table summarizes the key financial metrics for FY26 compared to FY25:

Total comprehensive income rose to ₹426.18 lakh from ₹366.94 lakh, aided by lower other comprehensive income losses. Current liabilities increased significantly to ₹399.67 lakh from ₹30.11 lakh, largely due to advances received against the sale of investments in process. Cash and cash equivalents remained stable at ₹4,242.91 lakh.

Strategic Transition and Capital Raise

Transchem is undergoing a significant business model shift from natural and pharmaceutical products to financial services, including stockbroking and portfolio management. Shareholders previously approved amendments to the Memorandum of Association and an increase in authorized share capital to ₹7,500 lakh. The company has proposed a preferential issue of up to 6.15 crore warrants at ₹75 per warrant, aggregating to ₹46,125 lakh, to identified non-promoter investors. This issuance awaits in-principle approval from BSE Limited. Furthermore, the Board has granted in-principle approval for the acquisition of 100% equity in Greshma Shares & Stocks Limited, subject to regulatory clearances from SEBI and stock exchanges.

What the Numbers Show

The divergence between total income and net profit highlights the company's transitional state. With zero revenue from core operations, profitability is sustained by investment income and one-time gains, such as the ₹156.58 lakh gain on the sale of immovable property. The rise in other expenses to ₹239.91 lakh, driven by professional fees and regulatory filing costs associated with the corporate restructuring, underscores the upfront capital intensity of this strategic pivot before any new revenue streams commence.

Transchem Limited has allotted 6,15,00,000 warrants on a preferential basis at an issue price of ₹75 per warrant to four non-promoter investors. The Preferential Issue Committee approved the allotment on June 03, 2026, following an in-principle approval from BSE Limited. The company received ₹115,31,25,000 as upfront payment, representing 25% of the warrant issue price, with the balance payable upon conversion into equity shares.

The warrants carry a right to subscribe to one fully paid-up equity share with a face value of ₹10 each. This right can be exercised during the period commencing from the date of allotment until the expiry of 18 months. The total issue size aggregates to ₹461,25,00,000, assuming full conversion of the warrants. There is no immediate change in the paid-up equity share capital of the company due to this allotment.

Allotment Details

The allotment was made to Bakkt Opco Holdings, LLC, Mr. Pishu V Chainani, JVS Holdings LLP, and Mr. Dhawal Jiwankumar Mehta. The table below details the number of warrants allotted and the subscription amount received from each investor.

Shareholding Pattern

Upon full exercise of the warrants, the allottees will hold a significant portion of the company's equity. Bakkt Opco Holdings, LLC is set to become the largest shareholder with a 64.42% stake, followed by Mr. Pishu V Chainani with 16.27%. The total post-preferential allotment shareholding for these investors will reach 83.40%.

The issuance was conducted in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and the applicable provisions of the Companies Act, 2013.